Advertisement Pfizer agrees to buy InnoPharma for $360m - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pfizer agrees to buy InnoPharma for $360m

Pfizer has entered into an agreement to acquire InnoPharma, a US-based pharmaceutical development company, for $360m.

As part of the deal, Pfizer will make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments.

The transaction, which is subject to the US regulatory approval, is expected to be completed during the third quarter of 2014.

InnoPharma has developed capabilities in complex injectable delivery forms, including pens and depot injectibles, and is working to use this expertise to expand into new dosage forms, including oral suspensions and nasals.

The existing portfolio of InnoPharma includes ten generic products approved by the US Food and Drug Administration (FDA), a pipeline of 19 products filed with FDA, and more than 30 injectable and ophthalmic products under development.

Currently, InnoPharma is looking to develop new formulations of existing drugs, including hard-to-make products, such as those that require complex manufacturing capabilities or have bio-equivalency challenges, in areas such as cancer and central nervous disorders.

Pfizer Injectables, a part of the Global Established Pharma business, includes manufacturing, production and sale of human pharmaceutical and surgiceutical products.